# US 2012/0252756 A1 · Pharmaceutical Compositions and Methods for Treating, Controlling, Ameliorating, or Reversing Conditions of the Eye

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252756 A1
- Document ID: US20120252756A1
- Status: Published application
- Kind: A1
- Application number: 13/469,853
- Filed: 2012-05-11
- Published: 2012-10-04
- Earliest claimed: 2010-06-25
- Inventors: Martin J. Coffey; Reza Haque; Ngumah Quintus; Mohannad Shawer; Jinzhong Zhang
- Web page: https://patentgrep.com/patent/US20120252756A1

## CPC

- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61K 31/4725: containing further heterocyclic rings
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 31/56: Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 27/02: Ophthalmic agents
- A61P 27/04: Artificial tears; Irrigation solutions
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/38: Cellulose; Derivatives thereof
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A pharmaceutical composition comprises a polyethylene glycol having a molecular weight in the range from about 1,000 to about 10,000, and a water-soluble cellulose derivative having a molecular weight in the range from about 50,000 to 120,000. The composition can further comprise boric acid and/or phosphate, a non-ionic surfactant, and/or an ophthalmic therapeutic agent. The composition is effective in treating, controlling, ameliorating, or reversing one or more conditions or symptoms of dry eye.

## Claims

### Claim 1

An ophthalmic composition comprising: (a) a polyethylene glycol having a molecular weigh in the range from about 1,000 to about 10,000 Da at a concentration from about 5 to about 15 percent by weight of the total composition; and (b) a non-ionic water-soluble cellulose derivative having a molecular weight in the range from about 50,000 to about 120,000 Da at a concentration from about 0.1 to about 5 percent by weight of the total composition.

### Claim 2 (depends on 1)

The pharmaceutical formulation of claim 1, wherein the polyethylene glycol has a molecular weigh in the range from about 2,000 to about 8,000 Da, and the non-ionic water-soluble cellulose derivative has a molecular weight in the range from about 60,000 to about 100,000 Da.

### Claim 3 (depends on 2)

The pharmaceutical formulation of claim 2, wherein the polyethylene glycol is selected from the group consisting of PEG-2000, PEG-3350, PEG-4000, PEG-6000, PEG-8000, and mixtures thereof; and the cellulose derivative is selected from the group consisting of hydroxypropylmethyl cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, methyl cellulose, and mixtures thereof.

### Claim 4 (depends on 3)

The pharmaceutical formulation of claim 3; wherein the concentration of the polyethylene glycol is in the range from about 7 to 12 percent by weight of the total composition, and the concentration of the cellulose derivative is in the range from about 0.3 to 2 percent by weight of the total composition.

### Claim 5 (depends on 4)

The pharmaceutical formulation of claim 4; wherein the polyethylene glycol is PEG-3350 or PEG-4000, and the cellulose derivative is hydroxypropylmethyl cellulose.

### Claim 6 (depends on 4)

The pharmaceutical formulation of claim 4, further comprising an ophthalmically acceptable therapeutic agent.

### Claim 7 (depends on 6)

The pharmaceutical formulation of claim 6; wherein the ophthalmically acceptable therapeutic agent is a compound having Formula II, V, or VI.

### Claim 8

An ophthalmic composition consisting essentially of: a polyethylene glycol having molecular weight in the range of 2,000 to 10,000; a non-ionic, water-soluble cellulose derivative selected from hydroxypropylmethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, and methyl cellulose; a non-ionic surfactant selected from polysorbate 20, 60, and 80; boric acid; a polyol selected from the group consisting of glycerin, propylene glycol, and mixtures thereof; at least a phosphate salt; an anti-oxidant; a chelating agent; a preservative; and water; wherein the composition has an osmolality in the range of 260-350 mOsm/kg, a pH in the range of 6.5-8, and a viscosity in the range of 2-500 centipoises.

### Claim 9 (depends on 8)

The ophthalmic composition of claim 8; wherein the polyethylene glycol is present at a concentration of 5-15 percent by weight of the total composition; the non-ionic, water-soluble cellulose derivative is present at a concentration of 0.1-2 percent by weight of the total composition; and the non-ionic surfactant is present at a concentration of 0.2-2 percent by weight of the total composition; and the polyol is present at a concentration of 0.01-2 percent by weight of the total composition.

### Claim 10

A method for treating, controlling, ameliorating, or reversing a condition of dry eye, the method comprising administering into an affected eye a composition that comprises: (a) a polyethylene glycol having a molecular weigh in the range from about 1,000 to about 10,000 Da at a concentration from about 5 to about 15 percent by weight of the total composition; and (b) a non-ionic water-soluble cellulose derivative having a molecular weight in the range from about 50,000 to about 120,000 Da at a concentration from about 0.1 to about 5 percent by weight of the total composition, in an amount and at a frequency effective to treat, control, ameliorate, or reverse said condition.

### Claim 11 (depends on 10)

The method of claim 10; wherein said condition is selected from the group consisting of discomfort in the eye, feeling of dryness, grittiness, stinging, irritation in the eye, and deficiency in production of a material of the tear film.

### Claim 12 (depends on 10)

The method of claim 10; wherein the polyethylene glycol has a molecular weigh in the range from about 2,000 to about 8,000 Da, and the non-ionic water-soluble cellulose derivative has a molecular weight in the range from about 60,000 to about 100,000 Da.

### Claim 13 (depends on 12)

The method of claim 12; wherein the polyethylene glycol is selected from the group consisting of PEG-2000, PEG-3350, PEG-4000, PEG-6000, PEG-800, and mixtures thereof; and the cellulose derivative is selected from the group consisting of hydroxypropylmethyl cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, methyl cellulose, and mixtures thereof.

### Claim 14 (depends on 13)

The method of claim 13; wherein the concentration of the polyethylene glycol is in the range from about 7 to 12 percent by weight of the total composition, and the concentration of the cellulose derivative is in the range from about 0.3 to 2 percent by weight of the total composition.

### Claim 15 (depends on 14)

The method of claim 14; wherein the polyethylene glycol is PEG-3350 or PEG-4000, and the cellulose derivative is hydroxypropylmethyl cellulose.

### Claim 16 (depends on 14)

The method of claim 14; wherein the composition further comprises an ophthalmically acceptable therapeutic agent.

### Claim 17 (depends on 16)

The method of claim 16; wherein the ophthalmically acceptable therapeutic agent is a compound having Formula II, V, or VI.

### Claim 18

A method for treating, controlling, ameliorating, or reversing a condition of dry eye, the method comprising administering into an affected eye a composition that consists essentially of: a polyethylene glycol having molecular weight in the range of 2,000 to 10,000; a non-ionic, water-soluble cellulose derivative selected from hydroxypropylmethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, and methyl cellulose; a non-ionic surfactant selected from polysorbate 20, 60, and 80; boric acid; a polyol selected from the group consisting of glycerin, propylene glycol, and mixtures thereof; at least a phosphate salt; an anti-oxidant; a chelating agent; a preservative; and water; wherein the composition has an osmolality in the range of 260-350 mOsm/kg, a pH in the range of 6.5-8, and a viscosity in the range of 2-500 centipoises, in an amount and at a frequency effective to treat, control, ameliorate, or reverse said condition.

### Claim 19 (depends on 18)

The method of claim 18; wherein the polyethylene glycol is present at a concentration of 5-15 percent by weight of the total composition; the non-ionic, water-soluble cellulose derivative is present at a concentration of 0.1-2 percent by weight of the total composition; and the non-ionic surfactant is present at a concentration of 0.2-2 percent by weight of the total composition; and the polyol is present at a concentration of 0.01-2 percent by weight of the total composition.

### Claim 20 (depends on 19)

The method of claim 19; wherein said condition is selected from the group consisting of discomfort in the eye, feeling of dryness, grittiness, stinging, irritation in the eye, and deficiency in production of a material of the tear film.

### Claim 21

A method for (1) treating, controlling, ameliorating, or reversing a condition of dry eye; (2) promoting corneal re-epithelization after being wounded; (3) providing protection to an ocular surface against desiccation-induced cell death; (4) supporting the integrity of a corneal surface exposed to hyperosmolar insults; (5) promoting production of mucin from an eye leading to improved lubrication of the corneal surface; and (6) promoting activation of cell signaling pathways involving EGFR, ERK, and Akt in a healing process of ocular wounds, the method comprising administering into an affected eye a composition that comprises: (a) a polyethylene glycol having a molecular weigh in the range from about 1,000 to about 10,000 Da at a concentration from about 5 to about percent by weight of the total composition; and (b) a non-ionic water-soluble cellulose derivative having a molecular weight in the range from about 50,000 to about 120,000 Da at a concentration from about 0.1 to about 5 percent by weight of the total composition, in an amount and at a frequency effective for said treating, controlling, ameliorating, reversing, promoting, or supporting.

### Claim 22 (depends on 21)

The method of claim 21; wherein the polyethylene glycol has a molecular weigh in the range from about 2,000 to about 8,000 Da, and the non-ionic water-soluble cellulose derivative has a molecular weight in the range from about 60,000 to about 100,000 Da; and wherein the composition further comprises a non-ionic surfactant and a polyol.

### Claim 23 (depends on 22)

The method of claim 22; wherein the polyethylene glycol is present at a concentration of 5-15 percent by weight of the total composition; the non-ionic, water-soluble cellulose derivative is present at a concentration of 0.1-2 percent by weight of the total composition; the non-ionic surfactant is present at a concentration of 0.2-2 percent by weight of the total composition; and the polyol is present at a concentration of 0.01-2 percent by weight of the total composition.
